



New Studies Confirm MiSight® 1 day Retinal Defocus Performance and Accommodative Behavior in High Myopes

CooperVision Presents Array of Myopia Control and Management Research at 2022 American Academy of Optometry Annual Meeting

SAN RAMON, Calif., October 25, 2022—New research from CooperVision, a global leader in myopia control and management, explores accommodative behavior and retinal defocus performance of MiSight® 1 day contact lenses in eyes with higher levels of myopia. Findings demonstrated that the dual focus optical design was able to introduce myopic defocus at all viewing distances.

With newly expanded parameters (up to -7.00 in Canada and the United States[†]), Eye Care Professionals can confidently treat more age-appropriate children impacted by the growing prevalence and severity of myopia.¹¹

Introduction of myopic retinal defocus in highly myopic eyes using a dual focus myopia control contact lens (Gantes et al.) and *Accommodative behavior and retinal defocus in highly myopic eyes fit with a dual focus myopia control contact lens* (Meyer et al.) are being presented at the [2022 American Academy of Optometry annual meeting](#) this week.

These scientific works examine highly myopic eyes (-6.50 to -10.00D, mean ± SD: -8.00±1.02D) fit with single-vision and MiSight® 1 day lenses, revealing that eyes accommodated similarly in both cases. Small accommodative leads at distance did not prevent +2.00D myopic defocus in the MiSight® 1 day treatment optics from being imposed on the retina. Researchers also found that higher powers did not prevent the lens from reducing hyperopic retinal defocus across the central 40 degrees of the horizontal retina.

“CooperVision has invested decades into myopia research and development to provide evidence-based interventions for children with this disease,” said Paul Chamberlain, BSc (Hons), Senior Director of Research Programs, CooperVision. “Combining these latest findings with our extensive and rigorous body of existing work helps eye care professionals take on myopia with more confidence, reaching even more children around the world.”

Chamberlain will present *MiSight® 1 day myopia control therapy assessment in fast and slow progressors*, a paper that describes the proportional treatment effect that allows faster-progressing children to receive the maximum myopia control benefit. The analysis is based on data gathered during years four through six of the international MiSight® 1 day clinical trial, when study participants were aged 11 to 15 years old. The Academy designated this work as one of the ten most newsworthy developments at the entire meeting. Chamberlain will preview the findings during the [Academy's global virtual press conference this evening](#).

Supporting CooperVision's comprehensive myopia management portfolio, *Efficacy of Fitting Ortho-K Contact Lenses Utilizing a Mobile Fitting Application* (Voltz et al)

demonstrates how lens parameters recommended by the Paragon CRT® Lens Calculator are in close alignment with those determined diagnostically, helping to save chair time. The company also funded *Preliminary Modification and Adaptation of a Quality of Vision Questionnaire for Children* (Postnikoff et al.), research surrounding the modernization of a quality of vision questionnaire to make it suitable for optical myopia control interventions with children.

These studies join multiple company-led and funded scientific papers and posters that will be presented at the American Academy of Optometry meeting, which takes place from October 26-29 in San Diego, California.

###

Presentation Schedule:

Wednesday, October 26

- 11 a.m. in Room 29CD: *Preliminary Modification and Adaptation of a Quality of Vision Questionnaire for Children* (Postnikoff et al.)

Thursday, October 27

- 3:30 p.m. in Room 29CD: *Accommodative behavior and retinal defocus in highly myopic eyes fit with a dual focus myopia control contact lens* (Meyer et al.)
- 4:15 p.m. in Room 29CD: *MiSight® 1 day myopia control therapy assessment in fast and slow progressors* (Chamberlain et al.)

Friday, October 28

- 1–3 p.m. in Exhibit Hall H, Poster Board #47: *Efficacy of Fitting Ortho-K Contact Lenses Utilizing a Mobile Fitting Application* (Voltz et al)
- 1–3 p.m. in Exhibit Hall H, Poster Board #161: *Introduction of myopic retinal defocus in highly myopic eyes using a dual focus myopia control contact lens* (Gantes et al.)

Canadian Indications for use: MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

† Up to -10.00D in select markets. Availability of specific expanded range parameters may vary by country

-

About CooperVision

CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.ca.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing

the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Media Contact

Hannah Barry, McDougall Communications for CooperVision
hannah@mcdougallpr.com or +1-585-645-8985

^[1] Holden et al, Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042